Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?

Radiology

Volumn 257, Issue 3, 2010, Pages 685-696

  Yang, Wei ^a,c   Ahmed, Muneeb ^a   Elian, Mostafa ^a,f   Hady, El Shymma A ^a,f   Levchenko, Tatyana S ^d   Sawant, Rupa R ^d   Signoretti, Sabina ^e   Collins, Michael ^e   Torchilin, Vladimir P ^d   Goldberg, S Nahum ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d NORTHEASTERN UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MINIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOXORUBICIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; LIPOSOME; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RAT; TUMOR VOLUME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HEAT-SHOCK PROTEINS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; PACLITAXEL; RATS; RATS, INBRED F344; STAINING AND LABELING;

EID: 78649659733     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10100500     Document Type: Article

References (43)

1. Dodd GD 3rd, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. RadioGraphics 2000;20(1):9-27.
2. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma. I. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005;185(1):64-71.
3. Goldberg SN, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities. I. J Vasc Interv Radiol 2001;12(9):1021-1032.
4. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008;9(7):621-628.
5. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234(3):961-967. (Pubitemid 40250844)
6. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214(3):761-768.
7. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221(1):159-166.
8. Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res 2009;39(3):231-240.
9. Yang W, Chen MH, Yin SS, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. AJR Am J Roentgenol 2006;186(5 suppl): S275-S283.
10. Chopra S, Dodd GD 3rd, Chintapalli KN, Leyendecker JR, Karahan OI, Rhim H. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol 2001;177(2):381-387.
11. Siperstein A, Garland A, Engle K, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7(2):106-113.
12. Horkan C, Dalal K, Coderre JA, et al. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology 2005; 235(1):81-88.
13. Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008; 49(2):217-222.
14. Grieco CA, Simon CJ, Mayo-Smith WW, DiPetrillo TA, Ready NE, Dupuy DE. Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol 2006;17(7):1117-1124.
15. D'Ippolito G, Ahmed M, Girnun GD, et al. Percutaneous tumor ablation: reduced tumor growth with combined radio-frequency ablation and liposomal doxorubicin in a rat breast tumor model. Radiology 2003;228(1): 112-118.
16. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005;235(2):469-477.
17. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005;16(10):1365-1371.
18. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002;179(1):93-101.
19. Demidenko ZN, Vivo C, Halicka HD, et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006;13(9):1434-1441.
20. Du XL, Jiang T, Wen ZQ, Gao R, Cui M, Wang F. Silencing of heat shock protein 70 expression enhances radiotherapy efficacy and inhibits cell invasion in endometrial cancer cell line. Croat Med J 2009;50(2):143-150.
21. Chen H, Yu YY, Zhang MJ, et al. Protective effect of doxorubicin induced heat shock protein 72 on cold preservation injury of rat livers. World J Gastroenterol 2004;10(9): 1375-1378.
22. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009; 20(7):1185-1192.
23. Tanaka Y, Fujiwara K, Tanaka H, Maehata K, Kohno I. Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. Int J Gynecol Cancer 2004; 14(4):616-620.
24. Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010;31(8): 2278-2292.
25. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 2000;63(1-2):19-30.
26. Koudelka S, Turánek-Knötigová P, Masek J, et al. Liposomes with high encapsulation capacity for paclitaxel: preparation, characterisation and in vivo anticancer effect. J Pharm Sci 2010;99(5):2309- 2319.
27. Ahmed M, Monsky WE, Girnun G, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003;63(19):6327-6333.
28. Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 2010;255(1):62-74.
29. Goldberg SN, Kruskal JB, Oliver BS, Clouse ME, Gazelle GS. Percutaneous tumor ablation: increased coagulation by combining radio-frequency ablation and ethanol instillation in a rat breast tumor model. Radiology 2000;217(3):827-831.
30. Monsky WL, Kruskal JB, Lukyanov AN, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002;224(3):823-829.
31. Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology 2001;220(2):420-427.
32. D'Souza GG, Wang T, Rockwell K, Torchilin VP. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res 2008;25(11): 2567-2572.
33. Kim SC, Yu J, Lee JW, Park ES, Chi SC. Sensitive HPLC method for quantitation of paclitaxel (Genexol ®) in biological samples with application to preclinical pharmacokinetics and biodistribution. J Pharm Biomed Anal 2005;39(1-2):170-176.
34. Liszczak TM, Hedley-Whyte ET, Adams JF, et al. Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol (Berl) 1984;65(2):150-157.
35. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88(11):2452-2463.
36. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89(2):175-184. (Pubitemid 27199890)
37. Thériault JR, Adachi H, Calderwood SK. Role of scavenger receptors in the binding and internalization of heat shock protein 70. J Immunol 2006;177(12):8604-8611.
38. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature . Cancer Res 2001;61(7):3027-3032.
39. Gnant MF, Noll LA, Terrill RE, et al. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999;126(5):890-899.
40. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55(17):3752-3756.
41. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45(4):649-656.
42. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992;13(4):134-136.
43. Moyer HR, Delman KA. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperthermia 2008; 24(3):251-261.